Almac’s Cancer DSA microarrays win recognition

December 24, 2007 — Almac Diagnostics’ Cancer DSA platform has won an award for the Best New Technology at the Tech Idol Showcase event held at the 2007 “Discovery 2 Diagnostics” conference in Pennsylvania, the company announced.

Cancer DSA research tools are microarrays developed to enable accelerated research in discovery, development and validation and ultimately to deliver clinical applications.

The tools are designed to work with both fresh frozen and paraffin embedded tissue, allowing applications in current clinical practice and retrospective tissue banks.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.